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Cardiac fibrosis occurs naturally after myocardial infarction. While the initially formed fibrotic tissue prevents the
infarcted heart tissue from rupture, the progression of cardiac fibrosis continuously expands the size of fibrotic
tissue and causes cardiac function decrease. Cardiac fibrosis eventually evolves the infarcted hearts into heart
failure. Inhibiting cardiac fibrosis from progressing is critical to prevent heart failure. However, there is no efficient
therapeutic approach currently available. Myofibroblasts are primarily responsible for cardiac fibrosis. They are
formed by cardiac fibroblast differentiation, fibrocyte differentiation, epithelial to mesenchymal transdifferentiation,
and endothelial to mesenchymal transition, driven by cytokines such as transforming growth factor beta (TGF-β),
angiotensin II and platelet-derived growth factor (PDGF). The approaches that inhibit myofibroblast formation
have been demonstrated to prevent cardiac fibrosis, including systemic delivery of antifibrotic drugs, localized
delivery of biomaterials, localized delivery of biomaterials and antifibrotic drugs, and localized delivery of cells
using biomaterials. This review addresses current progresses in cardiac fibrosis therapies.
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Myocardial infarction (MI) is the leading cause of death
in the western countries. Cardiac fibrosis naturally
occurs following MI. It is characterized by the excessive
deposition of extracellular matrix (ECM) typically colla-
gen in the infarcted area. Cardiac fibrosis increases
stiffness and decreases compliance of the infarcted
heart tissue. This negatively affects both contraction
and relaxation behavior of the heart, resulting in a
decrease in cardiac function. While the fibrotic tissue
that forms initially may protect the heart from rupture,
it gradually expands to the non-infarcted area when the
MI evolves from early to late stages. The continuous
increase of cardiac fibrosis leads to a progressive de-
crease in heart tissue contractility [1–5], and finally
causes heart failure [6–8]. Cardiac fibrosis occurs not
only after MI, but also from congenital defects, dilated
cardiomyopathy and hypertension [9].
A therapy that can inhibit cardiac fibrosis from pro-
gressing in the infarcted hearts will preserve cardiac
function and prevent heart failure. However, there is* Correspondence: guan.21@osu.edu
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are widely accepted to be responsible for cardiac fibrosis.
They secrete excessive ECM directly leads to the forma-
tion of scar tissue. They also express highly contractile
protein α-smooth muscle actin (αSMA) that remodels
the surrounding ECM [10]. Understanding the origin of
myofibroblasts may help to develop approaches to con-
trol tissue fibrosis.Sources of myofibroblasts in infarcted hearts
Cardiac fibroblasts differentiation into myofibroblasts
Cardiac fibroblasts have greater quantities than cardio-
myocytes in the heart tissue [11]. They are quiescent in
healthy heart tissue, and are responsible for ECM secre-
tion to keep the integrity of the interstitial matrix. They
can also transduce survival signals and therefore control
the conduction of electrical and mechanical stimuli to
help maintaining the systolic and diastolic function in
the heart tissue. Cardiac fibroblasts quickly respond to
the changes to the surrounding microenvironment. After
MI, the death of cardiomyocytes activates immune re-
sponse that induces cytokine and chemokine expression.
This initiates the infiltration of neutrophils and mono-
nuclear cells to the infarcted area. The neutrophils arele is distributed under the terms of the Creative Commons Attribution 4.0
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macrophages are able to secrete profibrotic cytokines
like transforming growth factor beta (TGF-β), Angioten-
sin II, and platelet-derived growth factor (PDGF) [12].
TGF-β binds to TGF-β receptors type I and II, and acti-
vates the TGF-β/Smad pathway to differentiate the car-
diac fibroblasts into myofibroblasts (Fig. 1) [10, 12].
TGF-β has been demonstrated as a major mediator of
myofibroblast formation after MI. The formed myofibro-
blasts then produce excessive ECM to initiate the car-
diac fibrosis. The myofibroblasts also secrete cytokines
such as TGF-β, Angiotensin II, PDGF, tumor necrosis
factor alpha (TNFα), and interleukin 1 beta (IL-1β) to
further enhance the differentiation of cardiac fibroblasts
into myofibroblasts. Angiotensin-II and PDGF indirectly
promote myofibroblast differentiation by increasing
TGF-β secretion [10].
Following myofibroblast differentiation, its number in-
creases over a period of a few months in the infarcted
area. More ECM is thus generated and deposited, lead-
ing to the increase of scar size. In the scar, the content
of collagen type III-rich fibers increases in a few weeks.
The fibers are then gradually replaced by stiffer type I
collagen. The scar tissue matures when the collagen fi-
bers are crosslinked. Unlike other scar tissues, myofibro-
blasts exist in the cardiac scar for many years, and
continue generating ECM [13].
Fibrocytes differentiation into myofibroblasts
Fibrocytes are a type of fibroblast-like peripheral cells
[14]. These cells express fibroblast specific proteins,
cluster of differentiation 31 and 45 (CD34 and CD45). In
response to chemokines such as chemokine (C-C motif )Fig. 1 TGF-β signaling in fibroblasts. Latent TGF-β binds to its type I and
noncanonical TGF-β–activated kinase-1 (TAK1)/p38/c-Jun N-terminal kinas
pathway resulting in induction of fibrogenic genes, such as α-smooth muligand 21(CCL21) and chemokine (C-X-C motif ) ligand
12 (CXCL12), fibrocytes migrate towards the injured
area [15]. Under the stimulation of TGF-β or
endothelin-1, fibrocytes differentiate into myofibroblast-
type cells with expression of α-SMA, production of fi-
bronectin and collagen, and loss of expression of CD34
and CD45 [16]. Besides TGF-β and endothelin-1, cyto-
kines including IL-13, IL-14 and PDGF also promote the
fibrocytes to differentiate into myofibroblasts [15, 17].Epithelial to mesenchymal transdifferentiation
Epithelial to mesenchymal transdifferentiation (EMT)
is another origin of myofibroblasts, which is a pro-
cess of transdifferentiation from epithelial cells into
myofibroblast-like cells. In the EMT process, the
expression of mesenchymal marker is up-regulated
while the expression of epithelial marker is down-
regulated [18, 19]. TGF-β1 plays a key role in this
process. While the roles of other cytokines in EMT
are still in debate, strong evidences suggest that
TNFα and IL-1β are capable of accentuating the
effect of TGF-β1 in driving EMT [20, 21].Endothelial to mesenchymal transition
Endothelial to mesenchymal transition (EnMT) is cur-
rently thought to be a potential origin of myofibroblasts.
EnMT was first proposed to be a phenomenon related
to embryonic development until evidence indicated that
up to 35 % of fibroblasts in fibrotic heart muscle are
converted from endothelial cells [22]. Similar to EMT,
EnMT can be driven by TGF-β (Types 1 and 2) and be
augmented by TNFα and IL-1β [22–24].II receptors, and activates the canonical Smad3/4 pathway and the
e (JNK) and NADPH oxidase 4 (NOX4)/reactive oxygen species (ROS)
scle actin (α-SMA) and collagen. (Reprinted from Leask A. [10])
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After MI, myofibroblasts differentiated from cardiac fi-
broblasts are mainly responsible for cardiac fibrosis.
Therefore, control of cardiac fibroblast differentiation
into myofibroblasts is critical to attenuate cardiac fibro-
sis. As discussed above, growth factors and cytokines like
TGF-β, Angiotensin-II, and PDGF directly and indirectly
involve in myofibroblast differentiation. Current therap-
ies are thus focused on reducing the secretion of these
growth factors and cytokines, and decreasing the
amount of active growth factors and cytokines. These
therapies include systemic delivery of antifibrotic agents,
localized delivery of biomaterials, localized delivery of
biomaterials and antifibrotic agents, and localized deliv-
ery of biomaterials and stem cells.
Systemic delivery of antifibrotic agents
Antifibrotic agents that decrease the activity or level
of growth factors and cytokines such as TGF-β,
Angiotensin-II, PDGF, TNFα and IL-1β can decrease
myofibroblast activation, thus decreasing cardiac fibro-
sis. Since TGF-β is considered as a major mediator for
cardiac fibroblasts to differentiate into myofibroblasts,
inhibiting TGF-β from attacking cardiac fibroblasts
and decreasing the amount of active TGF-β in the in-
farcted hearts may decrease the number of myofibro-
blasts. TGF-β receptor type I (ALK5) inhibitors like
GW 788388 have been developed to decrease TGF-β
activity [25]. Anti-TGF-β antibodies decrease the
amount of active TGF-β [10]. In addition, angiotensin-
converting enzyme (ACE) inhibitors are associated
with reducing TGF-β level [26, 27].
In cardiac fibroblasts, Angiotensin-II induces expres-
sion of TGF-β1 through angiotensin type-I receptor [28].
It also induces expression of collagen through TGF-β/
Smad pathway and extracellular signal-regulated kinase
by IL-6 dependent mechanism [29, 30]. Angiotensin re-
ceptor inhibitors like losartan have been shown to reduce
cardiac fibrosis in animal and human trials [31, 32]. In-
flammation plays a role in the formation and progression
of cardiac fibrosis. The cytokines released from macro-
phages and T cells, such as IL-1β and TNF-α, can pro-
mote the proliferation of cardiac fibroblasts and
upregulate the expression of tissue inhibitor of matrix
metalloproteinase (TIMP)-1, leading to cardiac fibrosis
[33]. Use of drugs to suppress inflammation in the heart
has shown benefits in reducing cardiac fibrosis. For ex-
ample the administration of the selective p38 MAPK in-
hibitor blocked the secretion of TNFα and decreased
cardiac fibrosis [34]. The drugs inhibiting cardiac fibro-
blast growth can also be used to inhibit cardiac fibrosis,
such as β-blockers, relaxin, and statins [35–37].
The above drugs for control of cardiac fibrosis are
generally administrated by a systemic delivery approachthrough either oral intake or injection. The major advan-
tage of this approach is that it is convenient. Yet the
drug dosage allocated to the infarcted heart may be low,
which decreases the therapeutic efficacy. Increase of the
initial drug dosage may cause toxic effect. In addition,
the drugs allocated to other tissues may have side effects
on these tissues and cells inside. Localized delivery of
antifibrotic drugs has the potential to address those
disadvantages.
Localized delivery of biomaterials
Biomaterials can be used to control cardiac fibrosis.
These biomaterials include naturally-derived matrices
such as collagen [38] and alginate [39], and synthetic
biomaterials such as poly(N-isopropyl acrylamide)-based
hydrogels [40]. Besides antifibrotic properties, these bio-
materials provide mechanical support to the infarcted
tissue and decrease elevated wall stress, resulting in im-
proved cardiac function [41].
Decellularized cardiac ECM is a naturally-derived
matrix that has shown promise for treating infarcted
hearts after MI [42]. It provides cells with tissue specific
biochemical cues important for cell migration and differ-
entiation, and tissue regeneration [42]. The major com-
position of decellularized cardiac ECM includes
collagen, elastin, fibronectin, and GAGs. While fibronec-
tin has been shown to promote cardiac fibroblasts to dif-
ferentiate into myofibroblasts to facilitate cardiac fibrosis
[43], the growth factors retained in the matrix such as
hepatocyte growth factor (HGF) may inhibit this differ-
entiation [44]. It is also possible that decellularized ECM
increases MMP-1 secretion in the infarcted hearts, thus
decreasing collagen deposition [45]. Injection of the
hydrogel based on decellularized porcine cardiac ECM
into rat MI model significantly decreased fibrosis in in-
farcted area [46].
In the infarcted hearts, elevated wall stress resulting
from left ventricle dilation represents a powerful stimu-
lus for intracellular signaling transduced by mechanore-
ceptors [47, 48]. The increased wall stress leads to the
activation of local tissue renin-angiotensin system, caus-
ing up-regulation of angiotensin II. The upregulated
angiotensin II increases tissue inflammation, and TGF-β,
IL-1β and TNF-α secretion [49–51]. These events lead
to the enhanced formation of myofibroblasts. Therefore,
use of biomaterials that can effectively decrease wall
stress will decrease tissue inflammation, resulting in de-
creased cardiac fibrosis. These biomaterials are soft with
modulus typically similar to or lower than that of the
heart tissue. On the other hand, biomaterials implant-
ation is always associated with foreign-body response
and inflammation, which may compromise the effect
from reduced wall stress. The choose of biomaterials
that cause less inflammation is thus critical.
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shown to decrease cardiac fibrosis [39]. The hydrogel
was highly soft with mean storage modulus of 20 ±
15 Pa. Injection of this hydrogel into infarcted rat hearts
significantly increased wall thickness, leading to the de-
crease of wall stress. As a result, the number of CD68+
macrophages was significantly decreased compared to
phosphate-buffered saline (PBS) injection [39]. The re-
duced tissue inflammation largely decreased tissue fibro-
sis after 8 weeks. In addition, injection of alginate and
chitosan enhanced tissue vascularization. The reduced
cardiac fibrosis and enhanced vascularization signifi-
cantly increased cardiac function. Similar results were
found when injecting soft collagen and poly(N-isopropy-
lacryamide-co-2-hydroxyl methacrylate-co-methacrylate-
polylactide) hydrogels into infarcted hearts [38, 47].
When using hydrogels to decrease cardiac fibrosis,
time of the injection affects therapeutic efficacy [38, 47].
This is because wall stress of the infarcted tissue varies
when the MI evolves from early to late stages. In gen-
eral, the wall stress gradually increases from the necrotic
phase to the fibrotic phase [52]. Therefore, the sameFig. 2 Effect of time and hydrogel injection on the expression of TNF-α (a)
differences between groups. Rats were divided into 3 injection treatment g
(2 W)) and 2 control groups (healthy and MI without treatments). (Reprintehydrogel may have different efficacy in reducing wall
stress and inflammation. In addition, the inflammation
at different stage of MI is different with the most severe
inflammation observed at the beginning of the MI [47].
Yoshizumi et al. found that the degree of inflammation
was significantly higher in hearts injected with the
hydrogel immediately after MI than in those injected
with hydrogel 3 days after MI [47]. As a result, the
hearts injected with the hydrogel 3 days after MI showed
the lowest cardiac fibrosis. When injecting the hydrogels
2 weeks after MI where the cardiac fibrosis was already
formed, the hydrogels did not decrease cardiac fibrosis
to the extent when they were injected 3 days after MI
(Figs. 2 and 3). The above results suggest that timing of
hydrogel injection should be considered in order to
achieve optimal therapeutic effect.
Localized delivery of biomaterials and antifibrotic agents
Localized delivery of antifibrotic agents has the potential
to address the low efficacy issue associated with the sys-
temic delivery as the dosage in the infarcted area is
higher. Yet the inherent disadvantage is that repeated, IL-1β (b) and IL-6 (c) in infarcted left ventricle. * indicates significant
roups (immediately after MI (IM), 3 d after MI (3D) and 2 w after MI
d from Yoshizumi et al. [47])
Fig. 3 Ventricular wall histology for rat hearts 10 w after MI. Rats were divided into 3 injection treatment groups (immediately after MI (IM),
3 d after MI (3D) and 2 w after MI (2 W)) and 2 control groups (healthy and MI without treatments). Representative Masson’s trichrome stained
cross-sections: a Healthy control, b MI control, c, f, i IM group, d, g, j 3D group, e, h, k 2 W group. A-H scale bars = 1 mm. Orange arrows point
to the hydrogel residues, black arrows point to foreign body giant cells. Wall thickness (l) and infarction size (m) were measured from the
complete set of these images. * indicates significant differences between groups. (Reprinted from Yoshizumi et al. [47])
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using minimally invasive surgery can avoid this issue.
However, repeated delivery increases cost for the therapy
and thereby is not ideal. These disadvantages may be
overcome by using drug delivery systems that continu-
ously release drugs. In these systems, the drugs are en-
capsulated in injectable biomaterials such as hydrogels
and microspheres. The drugs then gradually release from
the biomaterials by diffusion and biomaterial degrad-
ation. In addition, the biomaterials can increase drug re-
tention in the heart tissue.
Sustained delivery of drugs that decrease inflamma-
tion in the infarcted hearts after MI may decrease the
inflammation cytokines-associated myofibroblast for-
mation, thereby reducing cardiac fibrosis. Ibuprofen is
a cyclooxygenase inhibitor with anti-inflammatory
property. It directly inhibits leukocyte activation and
accumulations, and decreases the production of
leukocyte attractant and activator leukotriene B4 [53].
Vu et al. injected ibuprofen-containing hyaluronic acid
hydrogel into infarcted pig hearts, and found that car-
diac fibrosis was significantly decreased compared to
the hydrogel only group [53]. Erythropoietin (EPO)
shows a cardioprotective effect after acute MI [54]. It
augments cell survival in the infarcted hearts by acti-
vation of prosurvival signals Stat3, Akt, and ERK. Stat3
has been found to be closely related to tissue inflam-
mation. A deletion of Stat3 is susceptible to dramatic
increase of inflammation-induced cardiac fibrosis [54].
The activation of stat3 is thus expected to decrease
cardiac fibrosis. Kobayashi et al. encapsulated EPO in
the gelatin hydrogel and implanted into infarcted
hearts after acute MI [54]. The EPO was able to grad-
ually release from the hydrogel for 14 days. The re-
leased EPO significantly decreased cardiac fibrosis and
infarct size 14 days and 2 months after MI, leading to
the increase in cardiac function.
Delivery of antifibrotic growth factors represents an
effective approach to attenuate cardiac fibrosis. One of
the strong candidates is HGF. It is a potent agonist for
the tyrosine kinase surface receptor c-MET. HGF ex-
erts its antifibrotic property in two ways: inhibition of
collagen synthesis by suppression of TGFβ expression,
and degradation of collagen by activation of matrix
metalloproteinase-1 (MMP-1) [55]. In addition, HGF
may attenuate inflammation in the tissue, thereby de-
creasing inflammation-associated myofibroblast forma-
tion [56]. Besides antifibrotic property, HGF has pro-
angiogenic, anti-apoptotic and cardioprotective activity
[44, 55, 57–60]. Therefore, HGF is an attractive growth
factor for cardiac therapy. Taniyama et al. transfected
HGF gene in the cardiomyopathic hamsters and found
that cardiac fibrosis was significantly reduced and
angiogenesis was enhanced [55]. The disadvantage ofgene transfection approach lies in safety concern and in-
flammation associated with viral vectors. Direct delivery
of HGF may be an approach but has low efficacy due to
its short half-life in solution form. Sustained delivery of
HGF using biomaterials addresses this issue. Nakano et al.
developed a HGF delivery system using porous cross-
linked gelatin patch [61]. HGF was able to release from
the scaffold over 2 weeks. After 2 and 4 weeks of implant-
ation on the epicardium surface of the infarcted rat hearts,
the fibrotic area was significantly decreased from 17.5 %
(control, without implantation) to 8.8 %. The decrease of
cardiac fibrosis increased cardiac function as fractional
shortening and end-systolic elastance were significantly
greater in the HGF treatment group.
Clinical application of HGF especially recombinant
human HGF for cardiac therapy is obstructed by the
high cost, challenging to manufacture and short half-life
[62]. To increase the translational potential of HGF, Son-
nenberg et al. engineered a HGF biomimetic - HGF frag-
ment. The HGF fragment can be produced at a high
yield and show similar potency as HGF [63, 64]. In
addition, it is more stable than HGF. To deliver HGF
fragment into infarcted heart, it was encapsulated into a
hydrogel based on decellularized porcine epicardium.
The HGF fragment exhibited slow release kinetics,
resulting from the binding of HGF fragment with GAGs
in the hydrogel [46]. After delivery into infarcted hearts,
the released HGF fragment significantly downregulated
TGFβ expression and upregulated MMP-1 expression in
cardiac cells. Four weeks after injection, collagen content
in the infarcted area was significantly decreased com-
pared to control, indicating that the cardiac fibrosis was
attenuated.
Co-delivery of HGF and other growth factors can
also inhibit cardiac fibrosis. For example, HGF and
insulin-like growth factor-1 (IGF-1) were co-delivered
into infarcted hearts using alginate hydrogel as a car-
rier [65, 66]. IGF-1 has cytoprotective effect. It in-
creases cell survival in the infarcted hearts. The
decreased tissue apoptosis reduces fibrotic tissue for-
mation. The advantage of dual release is that IGF-1
and HGF can be sequentially released from the hydro-
gel. HGF released slower than IGF-1 due to a much
higher molecular weight. The first released IGF-1 pro-
moted cell survival while the latter released HGF de-
creased fibrotic tissue formation and stimulated
angiogenesis. Both growth factors were able to release
from the alginate for 7 days. The amount of released
IGF-1 was much higher than that of HGF [66]. The re-
leased growth factors remained bioactive. After being
delivered into infarcted rat hearts for 4 weeks, the dual
release group significantly decreased fibrotic area com-
pared to the alginate only group (Fig. 4). The released
growth factors also augmented cardiac cell survival.
Fig. 4 The sequential IGF-1/HGF delivery using alginate hydrogel reduces fibrosis. a Representative photomicrographs of Masson’s trichrome
staining (collagen-rich areas in blue and healthy myocardium in red), scar area. Bar = 500 μm. b Fibrotic content of the scar. * p < 0.05.
(Reprinted from Ruvinov et al. [66])
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growth factor (VEGF) can also decrease cardiac fibrosis
[67]. Salimath et al. encapsulated HGF and VEGF into
collagenase degradable PEG hydrogel [67]. When incu-
bated in PBS, both growth factors exhibited nearly linear
release from the hydrogel. In collagenase solution,
complete release was achieved in 4 days. After delivering
the release system into infarcted hearts for 3 weeks, the
non-treatment animals had fibrotic area of 41.5 % while
those treated with VEGF and HGF had only 13.9 %. The
combined VEGF and HGF treatment showed signifi-
cantly higher efficacy than individual growth factor treat-
ment. These results suggested that VEGF played a role
in reducing cardiac fibrosis. This may be the result of
VEGF promoting angiogenesis in the infarcted area [68,
69]. The vascularized tissue has reduced fibrosis. It is
also possible that VEGF and HGF synchronously re-
cruited progenitor cells for myocardial regeneration [67].
Basic fibroblast growth factor (bFGF) is another
growth factor that has been demonstrated to inhibit car-
diac fibrosis. The mechanism is that bFGF attenuates
cardiac fibroblasts to differentiate into myofibroblasts in
the presence of TGFβ [70]. While it is not clear whether
this effect is resulted only from blocking TGFβ/Smad
signaling pathway, studies based on valvular interstitial
cells suggested that TGFβ/Erk1/2 pathway may be also
involved [71–75]. One of the approaches to deliver bFGF
into infarcted hearts is to encapsulate it into crosslinked
albumin-alginate microcapsules followed by injection
[76]. The released bFGF substantially decreased collagen
content in the infarcted area. Co-delivery of bFGF with
HGF further reduced collagen content. This studydemonstrated that delivery of two antifibrotic growth
factors may more efficiently attenuate cardiac fibrosis.
Studies have shown that Notch1 signaling plays a
critical role in the cardiac fibroblast-myofibroblast
transformation, thereby affecting cardiac fibrosis
[77]. Notch1 activation is expected to inhibit the
transformation and prevent cardiac fibrosis. This can
be achieved by using Notch ligand Jagged-1 (peptide
CDDYYYGFGCNKFCRPR) [78]. To deliver the lig-
and into heart, it was encapsulated into a self-
assembling peptide-based hydrogel (peptide RARA
DADARARADADA). Three weeks after delivery,
picrosirius red staining results demonstrated that the
fibrotic area was significantly decreased compared to
self-assembling peptide control. Besides preventing
cardiac fibrosis, the Notch ligand also improved
angiogenesis, induced cardiac cell proliferation and
stem cell recruitment. Compared with growth factors
like HGF, VEGF, IGF-1 and bFGF, the peptide based
Notch ligand is less expensive yet possesses the
function of these growth factors in terms of prosur-
vival, proangiogenic, and antifibrotic properties.
Therefore, the peptide based cardiac therapy may
have greater translational potential.
Localized delivery of biomaterials and cells
Cell therapy represents a promising approach to treat
cardiac fibrosis. It may also lead to heart tissue
vascularization and regeneration. In fact, tissue
vascularization and regeneration can decrease fibrotic
tissue area. Various cell types have been explored in
clinical and preclinical models for cardiac therapy.
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cytes to directly regenerate cardiac tissue, but can indir-
ectly promote the regeneration. These cell types typically
provide paracrine effects to inhibit cardiac fibrosis, aug-
ment the survival of resident cardiac cells, recruit en-
dogenous stem cells, and vascularize the damaged heart
tissue [41, 79–84]. Some cell types also directly partici-
pate in tissue vascularization. Examples include bone
marrow mesenchymal stem cells (BMMSCs) [85–99] and
adipose-derived stem cells (ADSCs) [100–103]. Cardio-
myocytes and stem cells capable of differentiating into
cardiomyocytes can be used to regenerate cardiac tissue.
These stem cells include cardiac stem/progenitor cells
[104–108], pluripotent stem cell [embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs)]-de-
rived cardiovascular progenitor cells [109–111], and
cardiosphere-derived cells [112–122]. To deliver cells into
infarcted hearts, direct injection experiences low efficacy
because of inferior cell retention in the tissue. To increase
cell retention, cells can be encapsulated into injectable
materials such as hydrogels or microspheres. The cells
can also be loaded into porous scaffolds or hydrogels and
then patch on the tissue surface.
For those stem cells that indirectly promote heart tis-
sue regeneration, the cell paracrine effects may contrib-
ute to decreased fibrosis by decreasing inflammation and
profibrotic factor expression. Sun et al. encapsulated
ADSCs into platelet-rich fibrin and then patched on theFig. 5 Left ventricular (LV) myocardial histopathological changes on post-in
over LV after Masson’s Trichrome staining. e Mean fibrotic area. f–i Protein
and BBMP-2) biomarkers in infarct area of LV myocardium. * vs. other grou
MI. ADMSC: adipose derived MSC. PRF: platelet-rich fibrin. (Reprinted from Ssurface of infarcted hearts. Use of fibrin significantly in-
creased cell survival and paracrine effects, which led to
the significant decrease of the expression of fibrotic me-
diators TGF-β and Smad3 (Fig. 5). In addition, the ex-
pression of antifibrotic markers Smad1/5 and BMP-2
was significantly increased (Fig. 5) [123]. The enhanced
cell survival and paracrine effects also decreased the ex-
pression of inflammation markers CD3, CD40, CD68
and CD19. As a result, the fibrotic area was significantly
decreased as determined by Masson’s Trichrome stain-
ing (Fig. 5). When transplanting ADSCs in collagen
patches, the level of procollagen C-proteinase that is re-
sponsible for procollagen processing into mature colla-
gen was significantly reduced. In addition, the level of
lysyl oxidase, the enzyme involved in collagen crosslink-
ing in the peri-infarct region, was decreased [124]. These
events led to the decrease of cardiac fibrosis.
BMMSCs also contribute to decreased cardiac fibrosis.
BMMSCs have been found to attenuate cardiac fibro-
blast proliferation and collagen synthesis through para-
crine effects [125]. While it remains unclear how
paracrine effects decrease cardiac fibroblast proliferation,
the paracrine effects do downregulate the expression of
Col1a1 and Col3a1 [125]. BMMSCs also promote car-
diac fibroblasts to secrete matrix metalloproteinases that
degrade collagen [98]. Transplantation of BMMSCs into
infarcted hearts can attenuate cardiac fibrosis at different
stages of MI [126–128]. At the acute stage, the cardiacfarct day 42. a to d Microscopic identification of myocardial fibrosis
expressions of fibrotic (TGF-β and Smad3) and antifibrotic (Smad1/5
ps with different symbols (*, †, ‡, §), p < 0.05 for all groups. AMI: acute
un et al. [123])
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and progresses with time. Therefore, control of cardiac
fibrosis at acute MI stage may more efficiently attenuate
cardiac fibrosis. Ceccaldi et al. seeded BMMSCs into
microporous alginate-chitosan scaffolds and implanted
the constructs on infarcted area using acute MI model
[128]. After 33 days, the fibrosis percentage was de-
creased more in the BMMSCs seeded scaffolds than in
the pure scaffolds. Similar results were found when
injecting BMMSCs-encapsulated hydrogel into infarcted
mice hearts after acute MI. Xia et al. encapsulated
BMMSCs into a thermosensitive hydrogel based on N-
isopropylacrylamide/acrylic acid and 2-hydroxyletheyl
methacrylate-polycaprolactone [126]. After 28 days of
implantation, the collagen content in the scar tissue was
significantly decreased compared to transplantation of
BMMSC only. The decease of fibrosis may be resulted
from increased cell survival in the hydrogel, which pro-
vided greater paracrine effects to inhibit cardiac fibrosis.
BMMSC transplantation can also decrease cardiac fibro-
sis when the MI is in the subacute stage. Fiumana et al.
seeded BMMSCs into porous hyaluronan-based scaffolds
and placed on the top of the infarcted hearts two weeks
following MI [128]. After two weeks of implantation,
cardiac fibrosis was largely attenuated.
Implantation of cardiomyocytes that promote cardiac
tissue regeneration also has the potential to decrease
cardiac fibrosis. Joanne et al. seeded induced pluripotent
stem cells-derived cardiomyocytes (iPSC-CMs) into col-
lagen scaffolds with modulus similar to that of the native
heart tissue (10–15 kPa) [129]. After 3 days of in vitro
culture, the constructs were patched on the dilated
mouse hearts. Following 2 weeks of implantation, the
transplanted iPSC-CMs integrated with the native myo-
cardium and contributed to the cardiac fibrosis decrease.
The hearts implanted with constructs showed signifi-
cantly higher expression of osteopontin that regulates
matrix metalloproteinases than those implanted with
pure collagen scaffolds.
Conclusions
Control of cardiac fibrosis is essential to prevent the in-
farcted hearts from progressing into heart failure. The
cardiac fibrosis should ideally be controlled immediately
after MI so that the processes that initiate the cardiac fi-
brosis can be inactivated. Yet the heart tissue may rup-
ture without the protection of the initial fibrotic layer.
Cardiac fibrosis naturally expands upon the initial fi-
brotic tissue is formed. Inhibiting cardiac fibrosis from
progressing may prevent progressive deterioration of
cardiac function. Different approaches have been ex-
plored to treat cardiac fibrosis, such as systemic delivery
of antifibrotic drugs, localized transplantation of bioma-
terials, localized delivery of antifibrotic drugs usingbiomaterials, and localized delivery of cells and biomate-
rials. Compared to localized delivery approaches, the
systemic delivery approach is more convenient. How-
ever, the drug dosage allocated to the heart is limited,
resulting in lower therapeutic efficacy.
Localized transplantation of biomaterials controls car-
diac fibrosis by decreasing left ventricular wall stress to
decrease the elevated wall stress-induced inflammation.
When using decellularized ECM, the growth factor re-
leased from the matrix may also decrease cardiac fibro-
sis. Selection of biomaterials with suitable mechanical
properties is critical to decrease wall stress. The ideal
biomaterials should have elasticity and stiffness match-
ing those of the heart tissue. During the biomaterial deg-
radation, these mechanical properties may decrease. Yet
the cells from surrounding tissue may penetrate into the
biomaterials to vascularize the tissue, and promote re-
generation. Besides mechanical properties, the biomate-
rials should have excellent biocompatibility without
provoking significant inflammation.
Localized delivery of drugs and biomaterials exhibited
higher efficacy in controlling cardiac fibrosis than deliv-
ery of biomaterials only. The drugs and biomaterials
may be delivered into infarcted hearts shortly after MI
and before the initial fibrotic tissue is formed since the
biomaterials may provide adequate mechanical support
to prevent tissue rupture. The encapsulated drugs grad-
ually release from the biomaterials allowing for long-
term attenuation of cardiac fibrosis. The efficacy of car-
diac fibrosis inhibition is determined by drug release
kinetics. When the released drug is sufficient to prevent
new myofibroblast formation and ECM synthesis espe-
cially collagen, high efficacy can be achieved. Duration
of drug release also determine the therapeutic efficacy.
Longer time delivery better controls cardiac fibrosis.
Thus tailoring properties of the biomaterials to enable
the drugs to release for prolonged time period is
essential.
Localized delivery of cells using biomaterials has been
shown to be an effective approach to control cardiac
fibrosis. The cells either provide paracrine effects or
directly regenerate the infarcted heart tissue. Those cells
that provide paracrine effects may release antifibrotic
factors to directly control cardiac fibrosis. They may
release anti-inflammatory factors to control inflam-
mation thus indirectly controlling cardiac fibrosis. In
addition, the released angiogenic factors promote tissue
vascularization and regeneration. To long-term control
cardiac fibrosis, high rate of cell survival in the infarcted
hearts are necessary. However, the infarcted heart tissue
is characterized by a low nutrient and oxygen environ-
ment. The delivered cells thus experience low survival
rate. The inflammation condition in the infarcted hearts
also causes cell death. Use of biomaterials as cell carriers
Fan and Guan Biomaterials Research  (2016) 20:13 Page 10 of 13may increase the cell survival by protecting the cells
from attack by inflammatory cytokines, but do not
necessarily improve cell survival under the low nutri-
ent and oxygen conditions. Approaches that can be
used to increase cell survival under these conditions
include encapsulation of cells in biomaterials that re-
lease prosurvival growth factors such as bFGF, IGF-1
and HGF [130–135], and release oxygen [136].
In summary, different approaches have been used to
inhibit cardiac fibrosis. Localized drug delivery repre-
sents a major approach. Yet the widespread clinical ap-
plication of current approaches is obstructed by the low
therapeutic efficacy. Development of new and transla-
tional delivery approaches to improve therapeutic effi-
cacy is essential to push the anti-cardiac fibrosis therapy
towards clinical application. In addition, development of
new drugs that not only prevent myofibroblast forma-
tion but also revert existing myofibroblasts back into the
cardiac fibroblasts may fundamentally prevent cardiac
fibrosis.
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